Orthofix Medical Inc. (OFIX) News
Follow Orthofix Medical Inc. (OFIX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Orthofix Reports Q3 2026 Results and Revises Full-Year Guidance
Third-quarter sales rose 1.1%, adjusted EBITDA was $26.0 million and the net loss narrowed to $6.1 million. Orthofix cited distributor and supply constraints in Global Spine, offset by growth in Global Limb Reconstructio
EQUITY | Nov 09, 2026, 02:03 PM UTC
M
Orthofix Medical Q3 Revenue Misses, Cuts Full-Year Guidance
The company cited weaker U.S. Spine performance.
EQUITY | Nov 09, 2026, 12:20 PM UTC
M
Orthofix Medical Q3 Sales Reach $207.9 Million, Below Estimate
Q3 gross margin was 70.5%.
EARNINGS | Nov 09, 2026, 12:02 PM UTC
M
Orthofix Q3'26 Earnings Preview: EPS Estimated at (0.27) USD
Orthofix is scheduled to report Q3'26 results on November 9 before the market opens. Revenue is estimated at $210.52 million, with EPS estimated at (0.27) USD.
EQUITY | Nov 06, 2026, 12:00 PM UTC
L
OFIX - Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
OFIX - Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
EARNINGS | Aug 05, 2026, 11:08 AM UTC
L
Orthofix Medical Raises FY2026 Sales Guidance from $838.000M-$848.000M to $845.000M-$855.000M vs $843.311M Est
Orthofix Medical (NASDAQ: OFIX ) raises FY2026 sales outlook from $838.000 million-$848.000 million to $845.000 million-$855.000 million vs $843.311 million estimate.
EARNINGS | Aug 05, 2026, 11:03 AM UTC
H
OFIX Faces Insider Fiduciary Duty Probe
OFIX insiders allegedly breach duties
EQUITY | Jul 29, 2026, 03:01 PM UTC
H
Reported July 2, 2026: Orthofix Medical Says Medicare Will Restore Pre-May 18 Reimbursement Rates For Bone Growth Stimulators After CMS Reve
On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. Following that order, the Centers for Medicare
EARNINGS | Jul 06, 2026, 06:20 PM UTC
L
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Seer (NASDAQ: SEER ) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals (NASDAQ: UPC ) stock m
EQUITY | Jul 02, 2026, 09:05 PM UTC